Vaginal Dryness: Causes, Treatments & What Actually Works

You've probably heard "use more lubricant" so many times you want to throw the sample packets across the room. Here's the thing nobody's explaining well: vaginal dryness isn't just a friction problem. It's a tissue problem. And lube doesn't fix tissue.

More than half of postmenopausal women deal with vaginal dryness, but fewer than 25% ever discuss it with their doctor (NAMS, 2020). The ones who do often get dismissed with a shrug or handed an OTC brochure. That's a real problem, because this condition has FDA-approved treatments that work well, and most women have no idea they exist.

This article covers what's actually happening when vaginal tissue changes, what causes it beyond just menopause, the full range of treatments ranked by evidence, and the one myth that may be keeping breast cancer survivors from getting relief they deserve.

---

What Is Genitourinary Syndrome of Menopause?

Vaginal dryness is the symptom most women recognize. Genitourinary syndrome of menopause (GSM) is the full picture — and it's worse than most people realize.

In 2014, two major medical societies (the International Society for the Study of Women's Sexual Health and the North American Menopause Society) formally replaced the old term "vulvovaginal atrophy" with GSM because the original name missed the scope of what's happening (Portman & Gass, 2014). GSM includes not just vaginal changes but urinary symptoms, sexual dysfunction, and structural changes to the entire genitourinary system.

Without estrogen, the tissues of the vagina, urethra, and bladder gradually thin, lose elasticity, and shift to a higher pH. A healthy premenopausal vaginal pH sits around 3.8 to 4.5, kept acidic by lactobacilli that thrive in an estrogen-rich environment. After menopause, pH commonly rises to 5.0 to 6.5, which allows harmful bacteria to move in and good bacteria to die off (Caillouette et al., 1997; Hummelen et al., 2011). That microbiome shift is why GSM doesn't just cause dryness — it causes recurrent UTIs, urinary urgency, bladder irritability, and a whole cascade of symptoms that most women (and many doctors) never connect back to estrogen.

As urologist and sexual medicine specialist Dr. Rachel Rubin put it in a widely viewed clinical discussion: "The term vaginal dryness is killing women. What they don't understand is that this is something called genitourinary syndrome of menopause and it just gets worse and worse and worse over time without treatment, unlike hot flashes, which tend to go away."

GSM does not resolve on its own. That's the most important thing to understand about it.

What GSM actually feels like:

• Vaginal dryness, burning, irritation, or rawness
• Pain during sex (dyspareunia), reduced natural lubrication
• Difficulty reaching orgasm
• Recurrent urinary tract infections
• Urgency, frequency, or leaking urine
• Itching or awareness of genital tissues throughout the day

The NAMS 2020 position statement found that GSM affects 27% to 84% of postmenopausal women, with that range reflecting how many go undiagnosed (NAMS, 2020). The condition is likely far more common than even those numbers suggest.

---

What Causes Vaginal Dryness

Menopause is the most common cause, but it's far from the only one. Vaginal dryness can develop at any age when estrogen levels drop or tissue becomes irritated.

Menopause and Perimenopause

Estrogen is the primary hormone that maintains vaginal tissue health. When ovaries stop producing it, the vaginal epithelium (the surface layer of cells) thins, collagen breaks down, and lubrication decreases. This doesn't happen overnight. Many women in perimenopause (the 4 to 10 years before their final period) start noticing symptoms well before menopause is "official" (Nelson, 2008).

A Lancet review found that vaginal dryness is one of only two symptoms consistently and directly attributable to menopause across epidemiological studies. (The other is hot flashes. Everything else is more variable.) This means vaginal dryness is essentially universal if you live long enough after menopause without treatment.

Breastfeeding

Prolactin suppresses estrogen during lactation. Women who are breastfeeding often experience significant vaginal dryness and pain during sex that has nothing to do with age or menopause. It typically resolves after weaning, but for some women it's severe enough to need treatment in the meantime.

Medications That Drop Estrogen or Dry Tissue

Several common drugs cause vaginal dryness as a direct side effect:

Selective serotonin reuptake inhibitors (SSRIs): Antidepressants like sertraline and fluoxetine affect sexual function and can reduce natural lubrication. This affects women across age groups.

Antihistamines: The same mechanism that dries nasal passages dries vaginal tissue. Daily antihistamine use for allergies is an underrecognized contributor to vaginal dryness, especially in younger women.

Aromatase inhibitors: Women on these drugs for estrogen-receptor positive breast cancer (anastrozole, letrozole, exemestane) experience profoundly low estrogen levels. GSM is nearly universal in this group and often severe.

Tamoxifen: More complex. It acts as an estrogen blocker in breast tissue but an estrogen agonist elsewhere, so vaginal effects vary. Many women on tamoxifen still experience dryness.

Progestin-only contraception (Depo-Provera, some IUDs): Can suppress estrogen enough to cause atrophic symptoms.

GnRH agonists: Used for endometriosis, fibroids, or prostate cancer. These essentially induce chemical menopause and cause significant GSM.

Other Causes

Sjögren's syndrome (an autoimmune condition that affects moisture-producing glands) causes vaginal dryness as part of its broader dryness pattern. Radiation therapy to the pelvis causes severe vaginal atrophy and stenosis. Chemotherapy affects ovarian function. Even everyday irritants like scented pads, douching, and harsh soaps can damage vaginal epithelium and disrupt the microbiome, particularly in younger women whose tissue isn't yet compromised.

Women with uterine fibroids are sometimes placed on GnRH therapies that induce a temporary menopause-like state, which can trigger GSM symptoms even in their 30s and 40s.

---

FDA-Approved Treatments for Vaginal Dryness

There are four categories of FDA-approved options, plus OTC products and investigational therapies. Here's what the evidence actually shows.

Vaginal Estrogen: The Most Evidence-Based Option

Local vaginal estrogen is the most well-studied, most effective treatment for GSM. It works by restoring estrogen to the tissue directly, without the systemic absorption levels of oral or transdermal HRT.

A Cochrane systematic review of 30 randomized controlled trials found that all forms of vaginal estrogen (cream, tablet, ring) are similarly effective at improving vaginal atrophy symptoms, with no significant differences in efficacy between formulations (Lethaby et al., 2016). The review included over 19,000 women across trials and found that local vaginal estrogen significantly improves dryness, pH, vaginal cell maturation, and dyspareunia compared to placebo.

Available vaginal estrogen formulations:

Formulation	Brand	Dose	Schedule
Vaginal tablet	Vagifem	10 mcg estradiol	Nightly x 2 weeks, then 2x/week
Soft-gel insert	Imvexxy	4 or 10 mcg estradiol	Nightly x 2 weeks, then 2x/week
Vaginal ring	Estring	7.5 mcg/day estradiol	Replace every 90 days
Vaginal cream	Estrace, generics	0.01% estradiol	Nightly x 2 weeks, then 2x/week

Systemic absorption from vaginal estrogen is very low. At doses of 10 mcg estradiol (as in Vagifem), serum estradiol levels typically remain within normal postmenopausal ranges (Martel et al., 2016). This is the basis for why major medical guidelines support its use even in women with conditions that generally require low-estrogen environments.

Intrarosa (Prasterone): The Non-Estrogen Option That Still Works

Prasterone (sold as Intrarosa) is intravaginal DHEA (dehydroepiandrosterone) approved by the FDA in 2016. It's the first non-estrogen hormone therapy specifically indicated for dyspareunia and vaginal dryness due to GSM.

Here's why it's worth understanding. DHEA is a precursor hormone that the vaginal cells convert locally into both estrogens and androgens. Because conversion happens inside the tissue rather than in the bloodstream, serum estradiol levels after intravaginal prasterone remain well within normal postmenopausal values. The research shows levels actually running about 19% below the normal postmenopausal mean (Martel et al., 2016).

The clinical data is substantial. In a Phase III randomized controlled trial of 216 postmenopausal women, daily intravaginal 0.5% DHEA (6.5 mg) for 12 weeks produced highly significant improvements in all four FDA coprimary endpoints: percentage of parabasal cells, percentage of superficial cells, vaginal pH, and severity of the most bothersome symptom (Labrie et al., 2016). Vaginal dryness severity decreased by 42% versus placebo (p=0.013). Dyspareunia decreased by 46% over placebo (p=0.013).

A separate Phase III trial looking specifically at sexual function found that 12 weeks of daily intravaginal DHEA improved all six FSFI domains versus placebo — desire (49% improvement), arousal, lubrication, orgasm, satisfaction, and pain (Labrie et al., 2015). GSM treatment addresses sexual health from the tissue level up, which is a fundamentally different mechanism than drugs like how Viagra works for sexual dysfunction that address blood flow acutely. And across 52 weeks of treatment with 422 women, intravaginal DHEA showed no stimulation of the endometrium. All women maintained endometrial atrophy (Portman et al., 2015). Unlike systemic estrogen, there's no need for a progestin to protect the uterus.

Intrarosa is used once nightly and is available through telehealth providers. For women who want hormone-based tissue restoration without systemic estrogen, it's one of the most compelling options available.

Ospemifene (Osphena): The Oral Option

For women who can't or won't use anything vaginally, ospemifene (Osphena) is an FDA-approved oral selective estrogen receptor modulator (SERM) indicated for moderate-to-severe dyspareunia and vaginal dryness due to menopause, approved in 2013.

Ospemifene acts as an estrogen agonist in vaginal tissue (restoring tissue health) while acting as an antagonist or neutral in breast tissue. It's taken as a 60 mg tablet once daily with food. Clinical trials showed significant improvements in vaginal cell maturation and reduction in dyspareunia compared to placebo (Crandall et al., 2023). The main side effects are hot flashes (in about 7% of women) and a rare increase in DVT risk, similar to other SERMs. It should be used with caution in women at elevated clotting risk.

Systemic HRT for GSM

Systemic hormone replacement therapy (oral or transdermal estrogen) also treats GSM, though it's often prescribed primarily for vasomotor symptoms (hot flashes, night sweats). If you're already on systemic HRT and still experiencing vaginal dryness, adding low-dose vaginal estrogen or prasterone locally is often more effective for genitourinary symptoms than increasing systemic dosing (NAMS, 2020).

Understanding the perimenopause symptoms and treatment options helps clarify when systemic versus local therapy makes sense for your specific picture.

---

OTC Options: What Helps and What Doesn't

Over-the-counter products don't restore tissue. But they genuinely help symptoms, especially for mild-to-moderate vaginal dryness.

Vaginal Moisturizers

These are designed for regular use (every 2 to 3 days), not just during sex. They work by temporarily replenishing moisture in the tissue. The most evidence-backed option is Replens, which uses cross-linked polycarbophil to adhere to vaginal cells. A clinical review found that osmolality and pH matter significantly in product selection — products with very high osmolality (some personal lubricants run 8 to 30 times the osmolality of natural vaginal secretions) can actually damage epithelial cells (Edwards & Panay, 2015).

Hyaluronic acid vaginal gel is another well-supported OTC option. It's approved as a medical device in the EU and available OTC in the US. Studies have shown it performs comparably to low-dose vaginal estrogen for reducing dryness symptoms in mild-to-moderate GSM, though it doesn't restore tissue the way hormones do (Edwards & Panay, 2015).

Lubricants

Lubricants are for sex, not for tissue maintenance. They provide immediate relief during intercourse but don't address underlying tissue changes.

Water-based lubricants are the safest for most people, compatible with condoms and sex toys, and easy to wash off. Look for pH-balanced, low-osmolality options. Avoid products with glycerin (fermentable sugar that can feed yeast overgrowth), propylene glycol, or fragrances.

Silicone-based lubricants last longer and don't require reapplication. Not compatible with silicone sex toys (degrades the material). Good for people with water-sensitive skin or who want longer duration.

Oil-based lubricants (coconut oil, olive oil) work well but degrade latex condoms and can disrupt vaginal microbiome in some women. Fine for women who are not at risk for STIs and don't use latex.

---

The Breast Cancer Question: Is Vaginal Estrogen Safe?

This is where a lot of women get left out in the cold, and it's worth addressing directly.

Women who have had estrogen-receptor positive breast cancer are often told by well-meaning oncologists that they cannot use any estrogen. For systemic HRT, that caution is warranted. But vaginal estrogen is a different story, and the evidence has shifted significantly.

Because the systemic absorption from low-dose vaginal estrogen is so small, leading oncology and menopause organizations have updated their positions. NAMS states in its 2020 position statement that vaginal estrogen is an option for selected breast cancer survivors after discussion with their oncologist. The American College of Obstetricians and Gynecologists (ACOG) similarly supports its use for women with severe, refractory GSM.

The clinical trial evidence backs this up. A completed study evaluating Estring (the low-dose estradiol vaginal ring) in breast cancer patients on aromatase inhibitors showed no significant changes in serum estradiol levels after treatment. Multiple studies on Vagifem in this population have found similar results.

For breast cancer survivors on aromatase inhibitors, prasterone (Intrarosa) may be an even more suitable option because its mechanism is entirely intracellular: DHEA converts to active sex steroids within vaginal cells, with no meaningful change in serum estradiol. A Phase IV study (VIBRA study, NCT04705883) was completed specifically examining vaginal prasterone in breast cancer patients on aromatase inhibitors, with estradiol levels as the primary outcome.

The bottom line: if you've been told you can never use local vaginal therapy because of breast cancer history, that guidance may not reflect current evidence. Bring it up with an oncologist who is current on the literature, or ask for a referral to a menopause specialist.

---

CO2 Laser: What It Is and What It Isn't

The MonaLisa Touch and similar fractional CO2 laser systems get a lot of attention. Here's an honest accounting.

These devices are FDA-cleared for vaginal use (as lasers) but are not FDA-approved for the specific indication of treating GSM. That's a meaningful distinction. The laser creates controlled microablation of vaginal tissue, stimulating collagen production and tissue renewal. Clinical studies show improvements in GSM symptoms. One prospective trial of 77 women found significant improvement in all FSFI domains and vaginal symptom scores at 12 weeks, with 85% of previously sexually inactive women returning to sexual activity (Salvatore et al., 2015).

The FDA issued a safety warning in 2018 cautioning that laser devices had not been cleared or approved to treat vaginal dryness, GSM, or other menopause symptoms, and that claims of safety and effectiveness were not backed by well-designed clinical trials. That warning has tempered but not eliminated provider use.

Current evidence suggests CO2 laser may be beneficial, particularly for women who can't use hormone therapy, but it's investigational for this indication. It's not covered by insurance and costs $1,000 to $3,000 per treatment series (typically 3 sessions). If you're considering it, ask your provider specifically about the evidence and make sure you've first tried evidence-backed options.

---

Cost, Coverage & How to Get Started

What Things Actually Cost

Vaginal estrogen (Vagifem/Imvexxy): Retail price runs $150 to $250 per month, but generic estradiol vaginal cream is $30 to $80 per month and equally effective for most women. Many insurance plans cover vaginal estrogen.

Prasterone (Intrarosa): Around $200 to $300 per month at retail. Covered by some insurance plans; DHEA-based therapies have variable formulary placement. A manufacturer savings card is available and can reduce costs significantly for commercially insured patients.

Ospemifene (Osphena): Approximately $300 to $400 per month at retail. Generic versions have become available and are substantially cheaper. Insurance coverage is mixed.

OTC moisturizers and lubricants: $15 to $40 per month depending on frequency of use. Replens and hyaluronic acid gels are readily available.

CO2 laser: $1,000 to $3,000 for a 3-session series. Not covered by insurance. Maintenance sessions typically required annually.

Insurance and Coverage

Most major insurance plans (including Medicare Part D) cover vaginal estrogen products. Coverage for Intrarosa and Osphena is more variable. To get covered, you need a diagnosis code (N95.2, atrophic vaginitis of vagina) in your chart and a provider who documents medical necessity.

Telehealth providers can prescribe all of these treatments remotely after a clinical evaluation. You don't need an in-person gynecologic exam to get started with vaginal estrogen or prasterone in most cases.

How HEXIS Approaches This

At HEXIS, we start with your full hormonal picture. For women with GSM, that means understanding where you are in the menopause transition, what other symptoms you're managing, whether you're also on systemic HRT, and what your preferences are around hormones. Your provider will discuss all evidence-based options, including vaginal estrogen, prasterone, Osphena, and OTC approaches, and build a protocol that fits your situation.

If you've tried something that didn't work, or been told you "can't" use hormones without a real explanation of why, that conversation is worth having. Schedule a consultation to review your options with a physician who understands the current evidence.

---

Frequently Asked Questions

Is vaginal dryness only a menopause problem?

No. Vaginal dryness affects women at any age when estrogen levels drop. Breastfeeding, birth control pills (especially progestin-heavy formulations), SSRIs, antihistamines, and conditions like Sjögren's syndrome all cause it. One Reddit thread in r/birthcontrol with thousands of comments documents exactly this: women in their 20s dealing with significant dryness from hormonal contraception. If you're experiencing it, age doesn't determine whether treatment is warranted.

Can I use vaginal estrogen if I've had breast cancer?

Possibly yes, and this is different from what many women are told. Low-dose vaginal estrogen has minimal systemic absorption. Both NAMS and ACOG now support its use in selected breast cancer survivors after oncology consultation. Prasterone (Intrarosa) is another option with even lower systemic estrogen impact. The conversation to have is with a menopause-knowledgeable provider who is current on the evidence, not just "no hormones, ever."

What's the difference between a lubricant and a vaginal moisturizer?

Lubricants are for sex, applied immediately before or during intercourse for friction reduction. They don't treat the underlying tissue. Vaginal moisturizers are used regularly (every 2 to 3 days) for ongoing tissue hydration and are more effective for daily comfort. If you're using lubricant every day for basic comfort rather than just for sex, that's a sign you probably need a moisturizer or medical treatment.

How long does vaginal estrogen take to work?

Initial improvements in vaginal pH and cell maturation happen within 2 to 4 weeks. Most women notice meaningful relief in dryness and discomfort within 4 to 6 weeks. The 12-week mark is when the full tissue-rebuilding effect is measurable: pH normalizes, superficial cells increase, the microbiome shifts back toward lactobacilli dominance. Full benefits, including improved sexual function, continue to develop over 3 to 6 months of consistent use.

Why does sex hurt even though I'm aroused?

Arousal produces lubrication through the Bartholin's glands and vaginal transudation, but when tissue is atrophic (thin, less elastic, higher pH), even normal arousal may produce insufficient lubrication. The tissue itself is also less pliable. This isn't a psychological issue. It's a tissue issue. Treatment addresses the tissue, not just the symptom.

---

The Bottom Line

Vaginal dryness isn't just an inconvenience and it isn't inevitable. It's a manageable condition with multiple FDA-approved treatments backed by decades of trial data. The gap between what women experience and what they're actually offered comes down to awareness — often both the patient's and the provider's.

Low-dose vaginal estrogen and intravaginal prasterone (Intrarosa) are the most evidence-backed options for restoring vaginal tissue health. OTC moisturizers and lubricants help manage symptoms. Ospemifene gives women an oral option without vaginal application. CO2 laser shows promise but remains investigational for this indication.

If you have breast cancer history and have been told hormones are off-limits entirely, that conversation deserves a second look with someone current on the evidence.

Your genitourinary health is not separate from your overall health. Sexual function, urinary control, and comfort in your own body are worth treating at any age, at any stage of the menopause transition. If vaginal dryness is affecting your quality of life, Schedule a consultation to review what's right for your situation.

---